Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

124 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Can elective nodal irradiation be omitted in stage III non-small-cell lung cancer? Analysis of recurrences in a phase II study of induction chemotherapy and involved-field radiotherapy.
Senan S, Burgers S, Samson MJ, van Klaveren RJ, Oei SS, van Sörnsen de Koste J, Voet PW, Lagerwaard FJ, Maarten van Haarst J, Aerts JG, van Meerbeeck JP. Senan S, et al. Among authors: van klaveren rj, van meerbeeck jp, van sornsen de koste j. Int J Radiat Oncol Biol Phys. 2002 Nov 15;54(4):999-1006. doi: 10.1016/s0360-3016(02)03028-6. Int J Radiat Oncol Biol Phys. 2002. PMID: 12419425 Clinical Trial.
Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.
van Meerbeeck JP, Gaafar R, Manegold C, Van Klaveren RJ, Van Marck EA, Vincent M, Legrand C, Bottomley A, Debruyne C, Giaccone G; European Organisation for Research and Treatment of Cancer Lung Cancer Group; National Cancer Institute of Canada. van Meerbeeck JP, et al. Among authors: van klaveren rj, van marck ea. J Clin Oncol. 2005 Oct 1;23(28):6881-9. doi: 10.1200/JCO.20005.14.589. J Clin Oncol. 2005. PMID: 16192580 Clinical Trial.
A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03).
Gaafar RM, Surmont VF, Scagliotti GV, Van Klaveren RJ, Papamichael D, Welch JJ, Hasan B, Torri V, van Meerbeeck JP; EORTC Lung Cancer Group and the Italian Lung Cancer Project. Gaafar RM, et al. Among authors: van klaveren rj, van meerbeeck jp. Eur J Cancer. 2011 Oct;47(15):2331-40. doi: 10.1016/j.ejca.2011.06.045. Epub 2011 Jul 28. Eur J Cancer. 2011. PMID: 21802939 Clinical Trial.
History of tuberculosis as an independent prognostic factor for lung cancer survival.
Heuvers ME, Aerts JG, Hegmans JP, Veltman JD, Uitterlinden AG, Ruiter R, Rodenburg EM, Hofman A, Bakker M, Hoogsteden HC, Stricker BH, van Klaveren RJ. Heuvers ME, et al. Among authors: van klaveren rj. Lung Cancer. 2012 Jun;76(3):452-6. doi: 10.1016/j.lungcan.2011.12.008. Epub 2012 Jan 9. Lung Cancer. 2012. PMID: 22226628
Single-agent pemetrexed for chemonaïve and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program.
Taylor P, Castagneto B, Dark G, Marangolo M, Scagliotti GV, van Klaveren RJ, Labianca R, Serke M, Schuette W, van Meerbeeck JP, Heigener D, Liu Y, Adachi S, Blatter J, von Pawel J. Taylor P, et al. Among authors: van klaveren rj, van meerbeeck jp. J Thorac Oncol. 2008 Jul;3(7):764-71. doi: 10.1097/JTO.0b013e31817c73ec. J Thorac Oncol. 2008. PMID: 18594323 Free article.
Outcome of four-dimensional stereotactic radiotherapy for centrally located lung tumors.
Nuyttens JJ, van der Voort van Zyp NC, Praag J, Aluwini S, van Klaveren RJ, Verhoef C, Pattynama PM, Hoogeman MS. Nuyttens JJ, et al. Among authors: van klaveren rj, van der voort van zyp nc. Radiother Oncol. 2012 Mar;102(3):383-7. doi: 10.1016/j.radonc.2011.12.023. Epub 2012 Jan 20. Radiother Oncol. 2012. PMID: 22265734
124 results